Literature DB >> 32816731

Comparative In Vitro Activities of Ceftaroline and Tedizolid against Clinical Strains of Staphylococcus aureus and Enterococcus: Results from the China Antimicrobial Surveillance Network (CHINET) in 2018.

Yan Guo1,2, Yang Yang1,2, Yonggui Zheng1,2, Shi Wu1,2, Dandan Yin1,2, Demei Zhu1,2, Fupin Hu3,2.   

Abstract

The in vitro activities of ceftaroline and tedizolid were compared against Staphylococcus aureus, Enterococcus faecalis, and Enterococcus faecium clinical isolates collected from the China Antimicrobial Surveillance Network. Ceftaroline demonstrated potent activity against S. aureus isolates (MIC50/90, ≤0.25/1 mg/liter). Tedizolid was also highly active against S. aureus (MIC50/90, 0.25/0.5 mg/liter) and Enterococcus (MIC50/90, 0.5/0.5 mg/liter) isolates. Our results support the clinical usefulness of ceftaroline and tedizolid in treating Gram-positive infections.
Copyright © 2020 American Society for Microbiology.

Entities:  

Keywords:  Enterococcus faecaliszzm321990; Enterococcus faeciumzzm321990; Staphylococcus aureuszzm321990; antimicrobial susceptibility testing; ceftaroline; tedizolid

Year:  2020        PMID： 32816731      PMCID： PMC7577170          DOI： 10.1128/AAC.01461-20

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  8 in total

1.  Antimicrobial Susceptibility Trends among Staphylococcus aureus Isolates from U.S. Hospitals: Results from 7 Years of the Ceftaroline (AWARE) Surveillance Program, 2010 to 2016.

Authors:  Helio S Sader; Rodrigo E Mendes; Jennifer M Streit; Robert K Flamm
Journal:  Antimicrob Agents Chemother       Date:  2017-08-24       Impact factor: 5.191

Review 2.  Current Status and Trends of Antibacterial Resistance in China.

Authors:  Fupin Hu; Demei Zhu; Fu Wang; Minggui Wang
Journal:  Clin Infect Dis       Date:  2018-11-13       Impact factor: 9.079

Review 3.  Antibiotic resistance.

Authors:  Marianne Frieri; Krishan Kumar; Anthony Boutin
Journal:  J Infect Public Health       Date:  2016-09-06       Impact factor: 3.718

4.  Resistance reported from China antimicrobial surveillance network (CHINET) in 2018.

Authors:  Fupin Hu; Yan Guo; Yang Yang; Yonggui Zheng; Shi Wu; Xiaofei Jiang; Demei Zhu; Fu Wang
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2019-09-02       Impact factor: 3.267

Review 5.  Ceftaroline Fosamil: A Review in Complicated Skin and Soft Tissue Infections and Community-Acquired Pneumonia.

Authors:  Lesley J Scott
Journal:  Drugs       Date:  2016-11       Impact factor: 9.546

6.  In Vitro activities of Tedizolid and comparator antimicrobial agents against clinical isolates of Staphylococcus aureus collected in 12 countries from 2014 to 2016.

Authors:  James A Karlowsky; Meredith A Hackel; Samuel K Bouchillon; Jeff Alder; Daniel F Sahm
Journal:  Diagn Microbiol Infect Dis       Date:  2017-07-08       Impact factor: 2.803

Review 7.  Staphylococcus aureus infections: epidemiology, pathophysiology, clinical manifestations, and management.

Authors:  Steven Y C Tong; Joshua S Davis; Emily Eichenberger; Thomas L Holland; Vance G Fowler
Journal:  Clin Microbiol Rev       Date:  2015-07       Impact factor: 26.132

8.  Antimicrobial activity of ceftaroline against methicillin-resistant Staphylococcus aureus (MRSA) isolates collected in 2013-2014 at the Geneva University Hospitals.

Authors:  D O Andrey; P François; C Manzano; E J Bonetti; S Harbarth; J Schrenzel; W L Kelley; A Renzoni
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2016-10-15       Impact factor: 3.267
  8 in total
  1 in total

Review 1.  Pharmacokinetics and Pharmacodynamics of Tedizolid.

Authors:  Khalid Iqbal; Aliki Milioudi; Sebastian Georg Wicha
Journal:  Clin Pharmacokinet       Date:  2022-02-07       Impact factor: 6.447
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.